(firstQuint)Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer.

 The investigators would like to see if women at increased risk for breast cancer are likely to tolerate SDG daily for 12 months without significant side effects or changes in their menstrual cycles.

 The investigators would also like to determine if Brevail(R) can reduce breast cell proliferation in pre-menopausal women.

.

 Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer@highlight

The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at increased risk for development of breast cancer.

